ISO 10993-1:2025 · Gap Assessment
Independent ISO 10993-1:2025 Gap Analysis for Your BEP/BER
Get an independent ISO 10993-1:2025 gap analysis of your existing Biological Evaluation Plan (BEP) and Biological Evaluation Report (BER). We map your dossiers to the biological effects view, review how severity, probability, and uncertainty are documented in line with ISO 14971 concepts, and identify where chemistry (ISO 10993-18) and toxicological risk assessment (TRA, ISO 10993-17:2023) are not clearly connected to conclusions. No templates. No scorecards. No drafts—analysis only.
Independent analysis only
Effects-based ISO 10993-1:2025 view
ISO 14971-aligned risk estimation review
When an ISO 10993-1:2025 Gap Assessment Is the Right Move
Situations where a focused, independent gap report is more useful than another template or checklist:
- Your BEP/BERs were built to earlier ISO 10993-1 editions and still follow an “endpoint list” rather than a biological effects view.
- You need to know, in concrete terms, how your dossiers align with the 2025 edition’s expectations for severity, probability, uncertainty, and foreseeable misuse.
- Chemistry (ISO 10993-18) and toxicological risk assessments (TRA, ISO 10993-17:2023) exist, but it is unclear in the file how these inputs support your conclusions.
- Internal teams lack time or distance to critically review their own dossiers against the updated risk-management framing.
- You want a concise, reviewer-oriented assessment—not another tool, scorecard, or draft document.
What You Receive: One ISO 10993-1:2025 Gap Report
This service delivers a single, consolidated ISO 10993-1:2025 Gap Report. No templates, scorecards, BEP/BER drafts, or transition plans are included—this is analysis only.
Portfolio Mapping to Biological Effects (2025 View)
- Mapping of devices and contact categories/durations to the biological effects tables implied by ISO 10993-1:2025.
- Identification of where your current BEP/BER structure still reflects legacy endpoints instead of effects.
- Notes on consistency across your portfolio (e.g., similar devices evaluated differently).
Risk-Estimation Review
- Review of how severity, probability, and uncertainty are documented, using ISO 14971-style risk estimation concepts as emphasized in ISO 10993-1:2025.
- Assessment of whether acceptance criteria and rationales are clearly stated and traceable.
- Comments on how foreseeable misuse has been considered (or not) where it is realistically relevant.
Evidence Gaps & Missing Rationales
- Identification of missing or weak rationales for key biological effects or decisions.
- Pointers to where chemistry (ISO 10993-18) and toxicological risk assessment (ISO 10993-17:2023) inputs are required or not sufficiently linked to conclusions.
- Flagging of dossiers where existing literature, clinical history, or other evidence may be insufficient to support current positions.
No templates, scorecards, BEP/BER drafts, or transition plans are included—this is analysis only.
Why Teams Choose Sobel for Independent ISO 10993-1 Gap Reviews
Sobel acts as a critical, precise external reader for your biological evaluation documentation—focusing on how reviewers interpret your files, not on selling generic tools.
- Independent perspective on how your dossiers align with the ISO 10993-1:2025 biological effects view and ISO 14971-style risk estimation.
- Tight focus on one outcome: a concise, prioritized gap report—not templates, scorecards, or ready-made drafts.
- Strong emphasis on how chemistry (ISO 10993-18) and toxicological risk assessment (TRA, ISO 10993-17:2023) support sufficiency judgments.
- Clear explanations of where rationales are robust, weak, or missing, written in reviewer-oriented language.
- Experience across multiple markets (EU, FDA, Brazil and others), reflecting how authorities frame ISO 10993-1 within the broader risk-management process.
How We Work on the Gap Assessment (5 Steps)
A focused process to evaluate your current state against ISO 10993-1:2025, without drifting into drafting or template work.
Discovery & intake
- Collect device list, intended use, materials, patient contact categories and durations, existing BEPs/BERs, and available ISO 10993-18 chemistry reports and ISO 10993-17:2023 TRA materials.
Map to the 2025 structure
- Convert your legacy endpoint framing into the 2025 biological effects view, noting where foreseeable misuse should be considered based on realistic patterns.
Risk-estimation review
- Assess how severity, probability, uncertainty, and acceptance criteria are documented, and how well they reflect ISO 14971 concepts as emphasized in ISO 10993-1:2025.
Evidence appraisal
- Review literature, chemistry (ISO 10993-18), toxicology (ISO 10993-17:2023), and other evidence to judge sufficiency. Flag where inputs are missing, inconsistent, or weakly justified.
Gap report handover
- Deliver the single consolidated ISO 10993-1 Gap Report with prioritized findings, including clear indications of where updates, clarifications, or additional testing may be justified. No templates or drafts are produced.
Inputs We Need From Your Team
- Device list, intended use, materials, patient contact category (e.g. intact skin, mucosal, blood/tissue) and contact duration.
- Existing BEPs and BERs, including any internal evaluation procedures or standard formats.
- Chemistry reports (ISO 10993-18) and toxicological risk assessment materials (TRA, ISO 10993-17:2023 or equivalent).
- Target regions and submission routes (EU, FDA, other regulators) so we can reflect typical reviewer expectations and risk-management framing.
FREQUENTLY ASKED QUESTIONS
The 2025 edition strengthens the link to ISO 14971, reframes traditional “endpoints” into biological effects, and raises expectations for clear documentation of severity, probability, uncertainty, and foreseeable misuse. The gap assessment checks how well your current BEP/BERs reflect this.
No. This service is analysis only. We deliver a single ISO 10993-1 Gap Report with prioritized findings—no templates, scorecards, or tools are included.
No. We do not draft or revise BEPs/BERs as part of this service. We identify where updates are needed and why, but the output is a gap report, not new documents.
New tests are only recommended where residual risk or uncertainty remains after reviewing existing evidence. In the gap report, we indicate where additional testing may be justified, but we do not perform laboratory testing.
For a focused set of dossiers, timing is often 1–3 weeks from intake to gap report handover, depending on portfolio size and dossier maturity.
Get an Independent ISO 10993-1:2025 Gap Assessment
If your BEP/BERs still reflect earlier ISO 10993-1 editions, an independent gap assessment shows exactly where they fall short of the biological effects view and strengthened risk-estimation expectations—without forcing you into new templates or draft content you are not ready to adopt.
Contact Us
We would love to speak with you.
Feel free to reach out using the below details.
